Valeant Pharmaceuticals Announces 2017 Annual Meeting Of Shareholders Webcast And Q1 2017 Financial Results Conference Call

April 10, 2017

LAVAL, Quebec, April 10, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") today announced that it will conduct a live webcast of the Company's annual meeting of shareholders for the year-ended December 31, 2016.

The meeting will be held on Tuesday, May 2, 2017 at 9:00 a.m. ET at the Company's offices located at 2150 Saint Elzear Blvd. West, Laval, Quebec, Canada, H7L 4A8. Only shareholders of record at the close of business on the record date of March 7, 2017, will be entitled to vote at the meeting.

A live webcast and audio archive of the presentation will be available on Valeant's corporate website on the Investor Relations page, under the Events and Presentations tab and via this URL: http://ir.valeant.com/events-and-presentations

First Quarter 2017 Financial Results Conference Call

The Company also announced that it plans to release first quarter 2017 financial results on Tuesday, May 9, 2017. Valeant will host a conference call and live webcast at 8:00 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations portion of the corporate website before the start of the conference call.

Conference Call Details

Date	Tuesday, May 9, 2017
Time	8:00 a.m. ET
Webcast	http://ir.valeant.com/events-and-presentations
Participant Event Dial-in	(877) 876-8393 (North America)
	(443) 961-0178 (International)
Participant Passcode	1757022
Replay Dial-in	(855) 859-2056 (North America)
	(404) 537-3406 (International)
Replay Passcode	1757022 (replay available until June 9, 2017)

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com

Contact Information:

Elif McDonald 514-856-3855 877-281-6642 (toll free) elif.mcdonald@valeant.com

Media: Renée Soto or Chris Kittredge/Jared Levy Sard Verbinnen & Co. 212-687-8080

To view the original version on PR Newswire, visit:

http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-announces-2017-annual-me eting-of-shareholders-webcast-and-q1-2017-financial-results-conference-call-300437549.html



PERSONAL INFORMATION



LEGAL NOTICE PRIVACY POLICY Investor Inquiries

<u>ir@bauschhealth.com</u>

EMAIL ALERTS EMAIL PAGE RSS FEED

877-281-6642 EMAIL ALERTS EMAIL PAGE RSS FEE 514-856-3855 (Canada)

Use of this site signifies your agreement to
the Legal Notice and Privacy Policy.

Media inquiries
© 2025 Bausch Health Companies Inc. All rights

<u>Corporate.communications@bauschhealth.com</u> reserved. MTB.0230.USA.18 V2.0

908-569-3692

CALIFORNIA RESIDENTS: DO NOT SELL MY

